Sugi Predict

Sugi Predict / Compounds / SCHEMBL1379009

SCHEMBL1379009

SCHEMBL1379009

CC(C)(C)c1ccc(S(=O)(=O)Nc2n[nH]c3c(F)c(Cl)c(-c4ccccc4)cc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 2/20 0.55
▸ CDK1 P06493 1/20 0.55
▸ CDK2 P24941 1/20 0.55
▸ HSD17B2 P37059 5/20 0.42
▸ CCR9 P51686 4/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ SERPINE1 P05121 1/20 0.39
▸ TP53 P04637 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ UQCRB P14927 1/20 0.38
▸ BRD4 O60885 1/20 0.38
▸ PSD A5PKW4 1/20 0.38
▸ EDNRA P25101 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2334200 0.91 GSK3B (0.53) GSK3BCDK1CDK2EDNRA
SCHEMBL6532777 0.90 GSK3B (0.52) GSK3BCDK1CDK2EDNRA
SCHEMBL1377458 0.90 GSK3B (0.60) GSK3BCDK1CDK2KDM4EGAA
SCHEMBL1374941 0.89 GSK3B (0.57) GSK3BCDK1CDK2KDM4EALDH1A1
SCHEMBL1379072 0.89 GSK3B (0.57) GSK3BCDK1CDK2KDM4EMAPT
SCHEMBL1378226 0.86 GSK3B (0.55) GSK3BCDK1CDK2
SCHEMBL6528658 0.86 GSK3B (0.54) GSK3BCDK1CDK2KDM4EALDH1A1
SCHEMBL1379098 0.84 GSK3B (0.59) GSK3BCDK1CDK2KDM4EGAA
SCHEMBL6529436 0.84 GSK3B (0.52) GSK3BCDK1CDK2GAA
SCHEMBL1378973 0.82 GSK3B (0.64) GSK3BCDK1CDK2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4764168-B2 — — 2011-08-31 — — JP claimed
EP-1572200-B1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2011-08-17 — — EP claimed
US-7629374-B2 Use of aminoindazole derivatives for the inhibition of tau phosphorylation AVENTIS PHARMA SA (FR) 2009-12-08 — — US claimed
US-20080261997-A1 USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION AVENTIS PHARMA S.A. (FR) 2008-10-23 — — US claimed
US-7019011-B2 Aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2006-03-28 — — US claimed
EP-1572200-A1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-09-14 — — EP claimed
WO-2004062662-A1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-07-29 — — WO claimed
US-20040132794-A1 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2004-07-08 — — US claimed
EP-1572200-B1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2011-08-17 — — EP disclosed
US-7629374-B2 Use of aminoindazole derivatives for the inhibition of tau phosphorylation AVENTIS PHARMA SA (FR) 2009-12-08 — — US disclosed
US-20080261997-A1 USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION AVENTIS PHARMA S.A. (FR) 2008-10-23 — — US disclosed
US-7407981-B2 Aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2008-08-05 — — US disclosed
US-20070155735-A1 NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM AVENTIS PHARMA S.A. (FR) 2007-07-05 — — US disclosed
US-7196109-B2 Aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA SA (FR) 2007-03-27 — — US disclosed
US-20060074122-A1 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2006-04-06 — — US disclosed
US-7019011-B2 Aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2006-03-28 — — US disclosed
EP-1572200-A1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-09-14 — — EP disclosed
WO-2004062662-A1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-07-29 — — WO disclosed
US-20040132794-A1 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2004-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261997-A1 USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION OXSR1, CBR1, OXER1 GSK3B 159/4885CDK1 63/4885CDK2 549/4885
US-20040132794-A1 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them SIGMAR1, CYP2C8, CNR1 GSK3B 3595/4885CDK1 2123/4885CDK2 2237/4885
US-20070155735-A1 NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM CNR1, SUCNR1, CBR1 GSK3B 3542/4885CDK1 1006/4885CDK2 1855/4885
US-20060074122-A1 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them CNR1, SUCNR1, CBR1 GSK3B 3542/4885CDK1 1006/4885CDK2 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.